Development asset linked to Corvus Pharmaceuticals in public FDA and regional records.
pharma · Multiple Myeloma · Renal Cell Cancer · CRVS
Corvus Pharmaceuticals
Corvus Pharmaceuticals drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Burlingame, USA HQ
2014 Founded
48 Employees
Public company Type
CRVS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Burlingame, USA
- Founded
- 2014
- Employees
- 48
- Programs
- 9
- Drugs
- 4
- Patents
- 14
Corvus Pharmaceuticals pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Corvus Pharmaceuticals drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Corvus Pharmaceuticals in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Corvus Pharmaceuticals's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Corvus Pharmaceuticals in public FDA and regional records.